Lung CAncer SCreening in French women using low-dose CT and Artificial intelligence for DEtection: the CASCADE study protocol.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
08 12 2022
Historique:
entrez: 4 1 2023
pubmed: 5 1 2023
medline: 7 1 2023
Statut: epublish

Résumé

Lung cancer screening (LCS) using low-dose CT has been demonstrated to reduce lung cancer-related mortality in large randomised controlled trials. Moving from trials to practice requires answering practical questions about the level of expertise of CT readers, the need for double reading as in trials and the potential role of artificial intelligence (AI). In addition, most LCS studies have predominantly included male participants with women being under-represented, even though the benefit of screening is greater for them. Thus, this study aims to compare the performance of a single CT reading by general radiologists trained in LCS using AI as a second reader to that of a double reading by expert thoracic radiologists, in a campaign for low-dose CT screening in high-risk women. This observational cohort study will recruit 2400 asymptomatic women aged between 50 and 74 years, current or former smokers with at least a 20 pack-year smoking history, in 4 different French district areas. Assistance with smoking cessation will be offered to current smokers. An initial low-dose CT scan will be performed, with subsequent follow-ups at 1 year and 2 years. The primary objective is to compare CT scan readings by a single LCS-trained, AI-assisted radiologist to that of an expert double reading. The secondary objectives are: to evaluate the performance of AI as a stand-alone reader; the adherence to screening of female participants; the influence on smoking cessation; the psychological consequences of screening; the detection of chronic obstructive pulmonary disease (COPD), coronary artery disease and osteoporosis on low-dose CT scans and the costs incurred by screening. Ethics approval was obtained from the Comité de Protection des Personnes Sud-Est 1 (ethics approval number: 2021-A02265-36 with an amendment on 15 July 2022). Trial results will be disseminated at conferences, through relevant patient groups and published in peer-reviewed journals. NCT05195385.

Identifiants

pubmed: 36600392
pii: bmjopen-2022-067263
doi: 10.1136/bmjopen-2022-067263
pmc: PMC9743404
doi:

Banques de données

ClinicalTrials.gov
['NCT05195385']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e067263

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Int J Cancer. 2007 Jul 15;121(2):462-5
pubmed: 17373662
Nat Med. 2019 Jun;25(6):954-961
pubmed: 31110349
N Engl J Med. 2020 Feb 6;382(6):503-513
pubmed: 31995683
J Thorac Oncol. 2021 Jan;16(1):21-29
pubmed: 33384058
Lancet Reg Health Eur. 2021 Sep 11;10:100179
pubmed: 34806061
Lung Cancer. 2009 Apr;64(1):34-40
pubmed: 18723240
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Lung Cancer. 2008 Mar;59(3):355-63
pubmed: 17936405
Lancet Oncol. 2014 Nov;15(12):1332-41
pubmed: 25282285
Sensors (Basel). 2019 Aug 28;19(17):
pubmed: 31466261
J Oncol. 2021 Jan 12;2021:7836264
pubmed: 33519934
J Xray Sci Technol. 2020;28(4):591-617
pubmed: 32568165
Eur J Cancer Prev. 2012 May;21(3):308-15
pubmed: 22465911
Eur Radiol. 2012 Oct;22(10):2076-84
pubmed: 22814824
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Comput Med Imaging Graph. 2021 Jun;90:101883
pubmed: 33895622
Lancet Reg Health Eur. 2022 Aug 29;22:100492
pubmed: 36108315
Br J Radiol. 2016 Oct;89(1066):20160301
pubmed: 27461068
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
ESMO Open. 2019 Oct 13;4(5):e000577
pubmed: 31673428
J Thorac Oncol. 2009 May;4(5):608-14
pubmed: 19357536
Ann Oncol. 2019 Oct 1;30(10):1672
pubmed: 31168572
Int J Cancer. 2020 Mar 15;146(6):1503-1513
pubmed: 31162856
Health Technol Assess. 2016 May;20(40):1-146
pubmed: 27224642
Lancet Oncol. 2017 Dec;18(12):e754-e766
pubmed: 29208441
Transl Lung Cancer Res. 2021 May;10(5):2347-2355
pubmed: 34164282
J Natl Cancer Inst. 1996 Feb 21;88(3-4):183-92
pubmed: 8632492

Auteurs

Marie-Pierre Revel (MP)

Université Paris Cité, Paris, France marie-pierre.revel@aphp.fr.
Assistance Publique- Hopitaux de Paris, Cochin hospital Radiology department, Paris, France.

Hendy Abdoul (H)

Assistance Publique-Hopitaux de Paris, URC Necker/Cochin, Paris, France.

Guillaume Chassagnon (G)

Université Paris Cité, Paris, France.
Assistance Publique- Hopitaux de Paris, Cochin hospital Radiology department, Paris, France.

Emma Canniff (E)

Assistance Publique- Hopitaux de Paris, Cochin hospital Radiology department, Paris, France.

Isabelle Durand-Zaleski (I)

Université Paris Cité, Paris, France.
Assistance Publique- Hopitaux de Paris, Cochin hospital, Pulmonology Department, Paris, France.

Marie Wislez (M)

Université Paris Cité, Paris, France.
Pulmonology department, Cochin hospital, Assistance Publique - Hopitaux de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH